apexigen.comHealthcareFounded: 2010Funding to Date: $165.38MM
Apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by APXiMAB™, the Company’s proprietary antibody drug discovery platform.
For more details on financing and valuation for Apexigen, register or login.
View Enterprise Value for Apexigen.
To read this article and more news on Apexigen, register or login.